US/UK/Canada

Share

Pick a time period -
Tags ( Active)

INTERIM REPORT JANUARY-SEPTEMBER 2014 CHRONTECH PHARMA

· Research and development costs amounted to SEK 4.8 (1.7) m · Loss after tax was SEK -14.7 (9.1) m · Earnings per share were SEK -0.05 (0.04) · The company had no net sales for the period. · The Board continues to work to solve future liquidity and financing. · ChronTechs therapeutic hepatitis D vaccine activates an immune response that can enter the liver and eliminate liver cells that produce parts of HDV. · The Annual General Meeting (AGM) on June 18, 2014 resolved to adjourn until August due to negotiations regarding repurchase of the hepatitis technologies. · At

INTERIM REPORT JANUARY-JUNE 2014 CHRONTECH PHARMA

· Research and development costs amounted to SEK 0.5 (0.9) m · Loss after tax was SEK -2.3 (-3.6) m · Earnings per share were SEK -0.01 (-0.01) · The company had no net sales for the period · ChronTechs therapeutic hepatitis D vaccine activates an immune response that can enter the liver and eliminate liver cells that produce parts of HDV. · The Annual General Meeting (AGM) on June 18, 2014 resolved to adjourn until August due to negotiations regarding repurchase of the hepatitis technologies. EVENTS AFTER THE END OF THE REPORTING PERIOD · Another 902,896 convertibles

INTERIM REPORT JANUARY-MARCH 2014 CHRONTECH PHARMA

· Research and development costs amounted to SEK 0.4 (0.0) m · Loss after tax was SEK -1.4 (-1.5) m · Earnings per share were SEK -0.01 (-0.01) · The company had no net sales for the period · ChronTechs therapeutic hepatitis D vaccine activates an immune response that can enter the liver and eliminate liver cells that produce parts of HDV EVENTS AFTER THE END OF THE REPORTING PERIOD · Another 8,356,123 convertibles have been converted into shares during the period. 78,501,660 convertibles of the 100,862,727 convertibles subscribed for in September 2013 have now been

YEAR-END REPORT 2013 CHRONTECH PHARMA

· Research and development costs amounted to SEK 1.5 (13.9) m · Profit/loss after tax was SEK 7.5 (-19.7) m · Earnings per share were SEK 0.03 (-0.07) · Net sales SEK 15.1 (-) m · ChronTech has closed the deal concerning the sale of its hepatitis B and C technologies to the Irish company Avac Pharma Ltd. This means that ChronTech has received 625,000 USD, that the earlier loan of 625,000 USD has been assigned to Avac Pharma Ltd, another 1 million USD will be paid on or before the first anniversary of Closing. This payment amount to a total of 15.1 MSEK. Avac Pharma Ltd will

INTERIM REPORT JANUARY-SEPTEMBER 2013 CHRONTECH PHARMA

· Research and development costs amounted to SEK 1.7 (10.7) m · Profit/loss after tax was SEK 9.1 (-14.9) m · Earnings per share were SEK 0.06 (-0.08) · Net sales SEK 15.1 (-) m · ChronTech has closed the deal concerning the sale of its hepatitis B and C technologies to the Irish company Avac Pharma Ltd. This means that ChronTech has received 625,000 USD, that the earlier loan of 625,000 USD has been assigned to Avac Pharma Ltd, another 1 million USD will be paid on or before the first anniversary of Closing. This payment amount to a total of 15.1 MSEK. Avac Pharma Ltd will

ChronTechs rights offering of shares and convertibles oversubscribed

The result regarding ChronTech Pharma AB’s rights offering of shares and convertibles shows that the offering for subscribing for shares was oversubscribed by more than 100 % and that the offering for convertibles was slightly oversubscribed.The board of ChronTech Pharma AB decided on the 2nd of September, 2013 with the support of the authorization of the AGM about the present rights offering. One share gave two separate subscription rights, one concerning the subscription for one share at 0.03 SEK (totally 100,862,727 shares) and one concerning the subscription of one convertible at 0.06

ChronTech’s IVIN technology allows for lower vaccine doses with maintained efficacy

New studies have now shown that ChronTech’s IVIN technology is so efficacious that a far better immune response is achievable using the same or even much lower doses of DNA than when using a regular injection needle, irrespective of whether the injection is used in combination with in vivo electroporation or not. IVIN increases the number of vaccine specific T cells by more than 100% as compared to a regular needle when in combination with electroporation. Using IVIN strong immune responses can be achieved even when the dose is reduced 100-folds. The opportunity to reduce the amount of

Interim Report January-June 2013  ChronTech Pharma

· Research and development costs amounted to SEK 0.9 (6.7) m · The loss after tax was SEK -3.6 (-9.6) m · Earnings per share were SEK -0.02 (-0.05) · The company had no net sales for the period · ChronTech Pharma has received a bridge loan of 625 TUSD · At the extra general meeting (EGM) in ChronTech Pharma AB on the 16th of May it was resolved to accept the board’s proposal for restructuring of the company and transfer of the Company’s projects  regarding development of DNA-vaccines against hepatitis B and hepatitis C. · ChronTech holds the 20-percentage ownership in

Sale of hepatitis technologies completed

ChronTech has now closed the deal concerning the sale of its hepatitis technologies to the Irish company Avac Pharma Ltd in accordance with the Term Sheet previously published. This means that the Company has received another 625,000 USD, that the earlier loan of 625,000 USD has been assigned, another 1 million USD will be paid within a year, and that Avac Pharma Ltd will pay up to 1.5 million USD for the further development of ChronTechs injection technology IVIN. In accordance with the Term Sheet also 80,274,295 shares have been transferred to ChronTechs certified advisor Remium and the

Redemption of shares in ChronTech Pharma AB

In accordance with the decision of the Extra General Meeting on the 6th of May, 2013, the Swedish Companies Registration Office has now registered the redemption of 80,274,295 shares in ChronTech Pharma AB. At the EGM on the 6th of May it was decided “a reduction of the share capital with 2,408,228,85 SEK to cover the loss through the redemption of 80,274,295 shares. Those shareholders who will acquire the part of the Company’s activities regarding development of DNA vaccines against hepatitis B and hepatitis C shall put 80,274,295 shares to the Company’s disposition for redemption”. For

Report from the extra general meeting

At the extra general meeting (EGM) in ChronTech Pharma AB (below ”the Company”) on the 16th of May it was resolved to accept the board’s proposal for restructuring of the company and transfer of the Company’s projects regarding development of DNA-vaccines against hepatitis B and hepatitis C in accordance with the Term Sheet, which was put forward at the EGM and which earlier has been attached to the notice for the EGM. For more information, please contact: Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB Mobile phone: +46 709 28 05 28E-mail: anders.vahlne@chrontech.se

Report from the extra general meeting

At the extra general meeting (EGM) of ChronTech Pharma AB (below ”the Company”) on the 6th of May, 2013 it was resolved to reduce the share capital by means of redemption and cancellation of shares and to amend the articles of association. The resolution means that the share capital will be reduced by SEK 2,408,228.85 to cover losses by means of redemption and cancellation of 80,274,295 shares. The shares that will be redeemed and cancelled are owned by the group of shareholders that will buy approximately 70 per cent of the Company’s project regarding development of DNA vaccines against

INTERIM REPORT JANUARY-MARCH 2013 CHRONTECH PHARMA

· Research and development costs amounted to SEK 0.0 (3.2) m · The loss after tax was SEK -1.5 (-4.2) m · Earnings per share were SEK -0.01 (-0.02) · The company had no net sales for the period · ChronTech Pharma has received a bridge loan of 1.25 million USD · The three directors William W. Hall, Simon Kukes and John Climax have resigned from the board of directors of ChronTech Pharma AB Events after the end of the reporting period · ChronTech’s controlled clinical study of ChronVac-C® gives mixed results · At the extra general meeting (EGM) of ChronTech Pharma AB

Notice of Extra General Meeting

Shareholders in ChronTech Pharma AB (publ) are hereby summoned to an Extra General Meeting (EGM) Thursday the 16th of May 2013, at 14.00 at Kilpatrick Townsend Lawfirm’s office, Hovslagargatan 5 B, 5 tr in Stockholm. Application To participate in the EGM shareholders shall both be incorporated in the of Euroclear Sweden AB kept book of shareholders on the 10th of May 2013, and apply for participation at the EGM to the Company via mail at the address ChronTech Pharma AB, Hälsovägen 7, 141 57 Huddinge, per fax 08-449 84 81, per telephone 08-449 84 80, per e-post asa.ekstrand@chrontech.

ChronTech receives extended offer from a group of shareholder

As earlier has been communicated an extra general meeting (EGM) in ChronTech Pharma AB (the Company) on the 19th of April 2013 resolved to accept that a group of shareholders acquire a percentage of approximately 70 per cent of the Company’s projects regarding development of DNA vaccines against hepatitis B and hepatitis C. The group of shareholders has now offered to acquire the entire, i.e. also the remainder 30% and not only approximately 70% of the Company’s project regarding development of DNA vaccines against hepatitis B and hepatitis C. The purchase consideration now also includes

Report from the extra general meeting

At the extra general meeting (EGM) of ChronTech Pharma AB (below ”the Company”) on the 19th of April 2013 it was resolved to accept that a group of shareholders acquire a percentage of approximately 70 per cent of the Company’s project regarding development of DNA vaccines against hepatitis B and hepatitis C. This project will be transferred to a new company in which the Company thus will keep a share of approximately 30 per cent. As purchase-sum 1.25 MUSD will be paid in cash (of which the Company has already received 625,000 USD as a loan) and redemption and cancellation of altogether 80,

Notice of EGM

The Board of Directors of ChronTech has resolved to convene an EGM to be held on 6 May 2013 at 2.00 pm, please find the notice attached (only available in Swedish). For more information, please contact: Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB Mobile phone: +46 709 28 05 28,E-mail: anders.vahlne@ki.se About ChronTech ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and

Notice of EGM

The Board of Directors of ChronTech has resolved to convene an EGM to be held on 19 April 2013 at 2.00 pm, please find the notice attached (only available in Swedish). For more information, please contact: Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB Mobile phone: +46 709 28 05 28,E-mail: anders.vahlne@ki.se About ChronTech ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis

ChronTech’s controlled clinical study of ChronVac-C® gives mixed results

ChronTech now has made the first analysis of 12 weeks treatment with interferon and ribavirin in patients with (n=17) or without (n=12) two monthly previous vaccinations with 500 µg ChronVac-C® administered with Inovio’s Medpulser. No serious adverse events were noted and the number of moderate adverse events were lower in the vaccinated group than in the non-vaccinated group. At treatment week 12, 71 % of the vaccinated group had less than 15 international units of HCV RNA as compared to 58 % in the non-vaccinated group. As regards to number of patients who were virus negative at treatment

CHANGES TO THE CHRONTECH PHARMA BOARD OF DIRECTORS

The three directors William W. Hall, Simon Kukes and John Climax have as of today resigned from the board of directors of ChronTech Pharma AB. Hereafter, the board consists of Thomas Lynch (chairman), Prem Lachman, Matti Sällberg and Anders Vahlne. For more information, please contact: Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB Mobile phone: +46 709 28 05 28,E-mail: anders.vahlne@ki.se About ChronTech ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e.

CHRONTECH HAS RECEIVED A BRIDGE LOAN

Today ChronTech Pharma has received a bridge loan of 1.25 million USD to be paid in two tranches. The first tranche has been received and the second tranche will be received in approximately four weeks. The loan will be used to pay outstanding creditor's depts. The bridge loan is the first step in a refinancing and in the long run changes in the company structure.  For more information, please contact: Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB Mobile phone: +46 709 28 05 28,E-mail: anders.vahlne@ki.se About ChronTech ChronTech develops the therapeutic DNA

YEAR-END REPORT 2012 CHRONTECH PHARMA AB

· Research and development costs amounted to SEK 13.9 (15.2) m · The loss after tax was SEK -19.7 (-20.2) m · Earnings per share were SEK -0.11 (-0.17) · The company had no net sales for the period · The results from the controlled phase II clinical study of ChronVac-C® in combination with standard-of-care will be obtained and reported during Q1 2013 · The development of ChronTechs IVIN technology show promising results in small and large animals · The Board is working to solve the company’s financing · Opsonic Therapeutics, a company partly owned and co-founded by

INTERIM REPORT JANUARY-SEPTEMBER 2012 CHRONTECH PHARMA AB

· Research and development costs amounted to SEK 10.7 (10.5) m · The loss after tax was SEK -14.9 (-13.9) m · Earnings per share were SEK -0.08 (-0.14) · The company had no net sales for the period · The patient recruitment for the controlled phase II clinical study of ChronVac-C® in combination with standard-of-care is complete · The development of ChronTech’s IVIN technology progresses according to plan For more information, please contact: Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB Mobile phone: +46 709 28 05 28,E-mail: anders.vahlne@ki.se

There are no items matching the current filter
There are no more items matching the current filter
Back to top